Free tool
Drug Trial Radar: Neurology
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
85
Active, not recruiting, industry sponsors, Neurology, Phase 2
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting130
- Completed1,020
85 trials
Showing 1 to 25, recently updated first.
- "HB-adMSCs for the Treatment of Patients With Multiple Sclerosis"Active, not recruiting
Hope Biosciences Research FoundationIndustry
NCT06800404 · 10 participants · Start May 2, 2025 · Primary completion Jan 2027
Drug: Autologous HB-adMSCs · For: Relapsing Remitting Multiple Sclerosis (RRMS); Multiple Sclerosis
Sites: Sugar Land, Texas
- Safety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants With SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS)Active, not recruiting
UniQure Biopharma B.V.Industry
NCT06100276 · 20 participants (planned) · Start Aug 1, 2024 · Primary completion Dec 30, 2030
Drug: AMT-162 · For: Amyotrophic Lateral Sclerosis
Sites: Phoenix, Arizona; Irvine, California; San Francisco, California · 12 sites in all
- Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)Active, not recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06788912 · 60 participants (planned) · Start Mar 20, 2025 · Primary completion Feb 6, 2032
Drug: Pembrolizumab (neoadjuvant); Cisplatin and 11 more · For: Lung Neoplasm Malignant
Sites: Daphne, Alabama; Santa Barbara, California; Lone Tree, Colorado · 39 sites in all
- A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)Pivotal-lookingActive, not recruiting
Acumen PharmaceuticalsIndustry
NCT06335173 · 542 participants · Start Feb 29, 2024 · Primary completion Oct 29, 2026
Drug: sabirnetug; Placebo · For: Alzheimer Disease
Sites: Carlsbad, California; Fullerton, California; Irvine, California · 68 sites in all
- A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLCActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT04995523 · 212 participants · Start Sep 14, 2021 · Primary completion Jun 1, 2028
Drug: AZD2936 · For: Non-Small-Cell Lung Carcinoma
Sites: Chicago, Illinois; Rochester, Minnesota; Fairfax, Virginia · 40 sites in all
- A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)Pivotal-lookingActive, not recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06961006 · 160 participants (planned) · Start May 29, 2025 · Primary completion Jul 22, 2028
Drug: Intismeran autogene; Pembrolizumab · For: Malignant Melanoma
Sites: Springdale, Arkansas; San Francisco, California; Hackensack, New Jersey · 38 sites in all
- A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple SclerosisActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04075266 · 23 participants · Start Jan 9, 2020 · Primary completion Oct 5, 2023
Drug: Ocrelizumab · For: Multiple Sclerosis
Sites: Aurora, Colorado; Washington D.C., District of Columbia; Boston, Massachusetts · 12 sites in all
- A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)Active, not recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06780085 · 96 participants (planned) · Start May 13, 2025 · Primary completion Mar 12, 2032
Drug: Raludotatug Deruxtecan; Ifinatamab Deruxtecan and 4 more · For: Carcinoma, Non-Small-Cell Lung
Sites: Lexington, Kentucky; Baltimore, Maryland; Pittsburgh, Pennsylvania · 36 sites in all
- A Study to Evaluate the Safety and Biomarker Effects of RO7269162 in Participants at Risk for or at the Prodromal Stage of Alzheimer's Disease (AD)Pivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT06402838 · 256 participants · Start May 2, 2024 · Primary completion Nov 19, 2026
Drug: RO7269162; Placebo · For: Alzheimer's Disease
Sites: Santiago, Chile; Aarhus N, Denmark; Koebenhavn Oe, Denmark · 45 sites in all
- A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)Active, not recruiting
AskBio IncIndustry
NCT06285643 · 59 participants · Start Jun 11, 2024 · Primary completion Aug 31, 2028
Drug: AAV2-GDNF gene therapy · For: Parkinson Disease
Sites: Phoenix, Arizona; Irvine, California; Loma Linda, California · 46 sites in all
- A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal EpilepsyPivotal-lookingActive, not recruiting
Xenon Pharmaceuticals Inc.Industry
NCT03796962 · 325 participants · Start Jan 30, 2019 · Primary completion Sep 2, 2021
Drug: XEN1101 · For: Focal Epilepsy
Sites: Birmingham, Alabama; Mobile, Alabama; Phoenix, Arizona · 95 sites in all
- A Study of Botensilimab and Balstilimab for the Treatment of Colorectal CancerPivotal-lookingActive, not recruiting
Agenus Inc.Industry
NCT05608044 · 234 participants · Start Nov 30, 2022 · Primary completion Sep 2027
Drug: Botensilimab; Balstilimab and 1 more · For: Metastatic Colorectal Cancer
Sites: Scottsdale, Arizona; Duarte, California; Los Angeles, California · 65 sites in all
- A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's DiseaseActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07094516 · 96 participants · Start Aug 7, 2025 · Primary completion Sep 14, 2028
Drug: VHB937; VHB937 · For: Alzheimer's Disease
Sites: Phoenix, Arizona; Irvine, California; La Jolla, California · 73 sites in all
- A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's DiseaseActive, not recruiting
Janssen Pharmaceutica N.V., BelgiumJohnson & Johnson (Janssen) (JNJ)
NCT06544616 · 55 participants · Start Jul 22, 2024 · Primary completion Dec 22, 2026
Drug: JNJ-64042056; Placebo · For: Alzheimer Disease
Sites: Phoenix, Arizona; Irvine, California; Murrieta, California · 90 sites in all
- Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's DiseasePivotal-lookingActive, not recruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT06268886 · 310 participants (planned) · Start Mar 20, 2024 · Primary completion Dec 17, 2026
Drug: BMS-986446 · For: Alzheimer Disease, Early Onset
Sites: Chandler, Arizona; Gilbert, Arizona; Phoenix, Arizona · 176 sites in all
- A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia GravisActive, not recruiting
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT07501702 · 34 participants · Start May 13, 2026 · Primary completion Mar 2, 2029
Drug: Povetacicept; Placebo · For: Myasthenia Gravis, Generalized
Sites: Mission Hills, California; Boca Raton, Florida; Homestead, Florida · 31 sites in all
- Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia GravisPivotal-lookingActive, not recruiting
argenxargenx (ARGX)
NCT04833894 · 15 participants · Start Oct 26, 2021 · Primary completion Mar 2027
Drug: Efgartigimod IV · For: Generalized Myasthenia Gravis
Sites: Chicago, Illinois; Chapel Hill, North Carolina; Charlottesville, Virginia · 25 sites in all
- A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic MigrainePivotal-lookingActive, not recruiting
AbbVieAbbVie (ABBV)
NCT06602479 · 309 participants · Start Oct 7, 2024 · Primary completion Feb 2027
Drug: MEDI0618; Placebo · For: Migraine
Sites: Birmingham, Alabama; Huntsville, Alabama; Gilbert, Arizona · 71 sites in all
- VY7523-102: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in Participants With Early Alzheimer's DiseaseActive, not recruiting
Voyager TherapeuticsIndustry
NCT06874621 · 52 participants (planned) · Start Mar 3, 2025 · Primary completion Oct 13, 2026
Drug: VY7523; Placebo Comparator · For: Alzheimer's Disease (AD)
Sites: Los Angeles, California; Orange, California; San Francisco, California · 23 sites in all
- Effect of 10 mg Xanamem on Dementia Due to Alzheimer's DiseasePivotal-lookingActive, not recruiting
Actinogen MedicalIndustry
NCT06125951 · 247 participants · Start Apr 12, 2024 · Primary completion Sep 22, 2026
Drug: Xanamem; Placebo · For: Dementia Moderate; Dementia, Mild; Alzheimer Disease
Sites: Carlsbad, California; Sherman Oaks, California; Denver, Colorado · 34 sites in all
- A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)Pivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT07074886 · 193 participants · Start Nov 13, 2025 · Primary completion Sep 17, 2026
Drug: Ocrelizumab Test Formulation; Ocrelizumab Reference Formulation · For: Multiple Sclerosis
Sites: Carlsbad, California; Fort Collins, Colorado; Maitland, Florida · 49 sites in all
- Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)Active, not recruiting
Prevail TherapeuticsIndustry
NCT04127578 · 32 participants (planned) · Start Jan 3, 2020 · Primary completion Aug 31, 2031
Drug: LY3884961; Methylprednisolone and 1 more · For: Parkinson Disease
Sites: Scottsdale, Arizona; Murrieta, California; Englewood, Colorado · 15 sites in all
- Study of COYA 302 for the Treatment of ALSPivotal-lookingActive, not recruiting
Coya TherapeuticsIndustry
NCT07161999 · 120 participants (planned) · Start Oct 1, 2025 · Primary completion Apr 2027
Drug: COYA 302; Placebo · For: Amyotrophic Lateral Sclerosis (ALS)
Sites: Phoenix, Arizona; Los Angeles, California; San Francisco, California · 25 sites in all
- A Study to Evaluate the Effects of ACI-7104.056 in Patients With Early Stages of Parkinson's DiseasePivotal-lookingActive, not recruiting
AC Immune SAIndustry
NCT06015841 · 150 participants (planned) · Start Jul 24, 2023 · Primary completion Jun 2028
Drug: Placebo; ACI-7104.056 at Dose A and 2 more · For: Parkinson Disease; Parkinson Disease 6, Early-Onset
Sites: Bochum, Germany; Kassel, Germany; Kiel, Germany · 12 sites in all
- A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset EpilepsyPivotal-lookingActive, not recruiting
Biohaven Therapeutics Ltd.Industry
NCT06132893 · 390 participants (planned) · Start Mar 14, 2024 · Primary completion Dec 2026
Drug: BHV-7000; BHV-7000 and 3 more · For: Focal Epilepsy
Sites: Phoenix, Arizona; Tucson, Arizona; Little Rock, Arkansas · 104 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.